Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07872033
PHASE1

Aleniglipron Hepatic Impairment Study

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.

Official title: A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2026-10

Completion Date

2027-12

Last Updated

2026-10-13

Healthy Volunteers

No

Interventions

DRUG

Aleniglipron

administered orally

Locations (2)

Research Site

Orlando, Florida, United States

Research Site

San Antonio, Texas, United States